ATRX and pancreatic neuroendocrine tumor: In some models, such as in the pancreatic endocrine tumors, absence of ATRX nuclear expression by immunohistochemistry can be used as surrogate marker of ALT phenotype; however, it should not be used without other confirmatory techniques [14].